Skip to content

BrightSpring Health Services

US · BTSG #1332 by market cap Listed 2024
63.80 +0.05 +0.08%
Live - 5344 symbols - heartbeat 334s ago · 2026-10-08 07:00
Pre-market 63.65 -0.24%
After-hours 64.75 +1.49%
Overnight 64.04 +0.38%
Market cap
12.62B
P/B
6.16
EPS
0.87
Reader sentiment Are you bullish or bearish on BTSG?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 5.99 Expensive vs history 94th percentile
5-year average 3.05 · #32 of 41 in Health Information Services
P/E ratio 37.58 In line with history 55th percentile
5-year average 7.23 · forward 31.51 · #6 of 17 in Health Information Services
P/S ratio 0.85 Expensive vs history 93rd percentile
5-year average 0.42 · forward 0.75 · #13 of 42 in Health Information Services

Vs. peers Health Information Services

Company Market cap P/E (TTM) P/B Div yield
BrightSpring Health Services (BTSG) 12.62B 38.67 6.16 0.00%
Veeva Systems (VEEV) 45.74B 46.31 6.15 0.00%
Tempus AI (TEM) 12.69B -48.85 28.53 0.00%
Hinge Health (HNGE) 7.90B 73.14 22.93 0.00%
HealthEquity (HQY) 7.60B 33.18 3.82 0.00%
Waystar Holding (WAY) 4.94B 36.81 1.24 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value51.30 Economic moatNarrow UncertaintyHigh

Trading 19.6% above Morningstar's fair value estimate.

Fair value

BrightSpring Health Services Inc earns a 2-star quantitative star rating, indicating our belief that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 21% premium over our quantitative fair value estimate of $51.30 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 17.2%, which sits in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

Conversely, the firm's solid growth is reassuring. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. The firm's EPS 5-year growth of 43.7%, for example, sits in the top 10% compared with peers globally. The robust five-year track record of EPS growth is reason to be optimistic about the firm's shares. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 07:00:04 · For reference only, not investment advice and not tailored to your situation.